Chevy Chase Trust
NTLA icon

Chevy Chase Trust’s Intellia Therapeutics NTLA Stock Holding History

Chevy Chase Trust’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-288,321
Closed -$3.36M – 645
2024
Q4 		$3.36M Sell
288,321
-522,712
-64% -$8.16M 0.01% 544
2024
Q3 		$16.7M Sell
811,033
-231,592
-22% -$5.34M 0.05% 305
2024
Q2 		$23.3M Sell
1,042,625
-31,985
-3% -$762K 0.07% 216
2024
Q1 		$29.6M Buy
1,074,610
+83,435
+8% +$2.32M 0.1% 186
2023
Q4 		$30.2M Sell
991,175
-11,780
-1% -$339K 0.11% 172
2023
Q3 		$31.7M Buy
1,002,955
+29,412
+3% +$1.14M 0.13% 153
2023
Q2 		$39.7M Buy
973,543
+36,477
+4% +$1.48M 0.15% 135
2023
Q1 		$34.9M Sell
937,066
-35,010
-4% -$1.37M 0.14% 144
2022
Q4 		$33.9M Sell
972,076
-165,399
-15% -$7.86M 0.14% 143
2022
Q3 		$63.7M Buy
1,137,475
+101,170
+10% +$6.28M 0.27% 88
2022
Q2 		$53.6M Sell
1,036,305
-20,463
-2% -$1.04M 0.22% 99
2022
Q1 		$76.8M Sell
1,056,768
-81,336
-7% -$6.89M 0.26% 89
2021
Q4 		$135M Sell
1,138,104
-20,628
-2% -$2.58M 0.43% 49
2021
Q3 		$155M Sell
1,158,732
-87,839
-7% -$13.3M 0.54% 35
2021
Q2 		$202M Sell
1,246,571
-77,858
-6% -$6.06M 0.69% 26
2021
Q1 		$106M Sell
1,324,429
-311,443
-19% -$20.9M 0.38% 58
2020
Q4 		$89M Sell
1,635,872
-168,384
-9% -$6.11M 0.32% 75
2020
Q3 		$35.9M Buy
1,804,256
+246,093
+16% +$5.13M 0.14% 152
2020
Q2 		$32.8M Buy
1,558,163
+173,351
+13% +$2.94M 0.13% 161
2020
Q1 		$16.9M Buy
1,384,812
+51,987
+4% +$700K 0.08% 237
2019
Q4 		$19.6M Buy
1,332,825
+78,058
+6% +$1.09M 0.07% 265
2019
Q3 		$16.8M Buy
1,254,767
+154,922
+14% +$2.47M 0.07% 287
2019
Q2 		$18M Buy
1,099,845
+143,334
+15% +$2.25M 0.07% 274
2019
Q1 		$14.7M Buy
956,511
+261,175
+38% +$3.89M 0.06% 320
2018
Q4 		$9.49M Sell
695,336
-46,688
-6% -$868K 0.05% 379
2018
Q3 		$21.2M Buy
742,024
+86,142
+13% +$2.51M 0.09% 237
2018
Q2 		$17.9M Buy
655,882
+67,714
+12% +$1.64M 0.08% 270
2018
Q1 		$12.4M Buy
+588,168
New +$14.5M 0.06% 357

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Chevy Chase Trust's NTLA Position: Q1 2025 in Review

Chevy Chase Trust sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 288,321 shares — an estimated $3.36M sold.

Chevy Chase Trust first reported a position in NTLA in Q1 2018 and held it in 28 quarters. The position peaked at $202M in Q2 2021. 295 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Chevy Chase Trust reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Chevy Chase Trust sold 288,321 Intellia Therapeutics shares in Q1 2025, an estimated $3.36M.
  • Chevy Chase Trust first reported a position in Intellia Therapeutics in Q1 2018 and held it in 28 quarters.
  • Chevy Chase Trust's Intellia Therapeutics position peaked at $202M in Q2 2021.
  • 295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Chevy Chase Trust's 13F filing for Q1 2025, filed 23 Apr 2025.